UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000009641
Receipt number R000011309
Scientific Title Evaluation of the influence of Vildagliptin on chorioretinal blood flow in patients with diabetic retinopathy
Date of disclosure of the study information 2012/12/31
Last modified on 2013/12/27 16:59:07

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of the influence of Vildagliptin on chorioretinal blood flow in patients with diabetic retinopathy

Acronym

Evaluation of the influence of Vildagliptin on chorioretinal blood flow in patients with diabetic retinopathy

Scientific Title

Evaluation of the influence of Vildagliptin on chorioretinal blood flow in patients with diabetic retinopathy

Scientific Title:Acronym

Evaluation of the influence of Vildagliptin on chorioretinal blood flow in patients with diabetic retinopathy

Region

Japan


Condition

Condition

diabetic retinopathy

Classification by specialty

Endocrinology and Metabolism Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare the influences of vildagliptin or other oral hypoglycemic drugs on chorioretinal blood flow and other structural and functional visual outcomes in patients with type 2 diabetes and diabetic retinopathy.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

chorioretinal blood flow

Key secondary outcomes

best corrected visual acuity, intraocular pressure, central retinal thickness, HbA1c, fasting blood glucose


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Pseudo-randomization


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Add each treatment for 6 months.
1) vildagliptin 50 or 100mg/day

Interventions/Control_2

2) other oral hypoglycemic drugs except anti-dipeptidyl peptidase-4 (DDP-4) inhibitor

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Type 2 diabetic patients who meet the following requirements
1) Diabetic retinopathy requiring treatment
2) 6.9%<=HbA1c<=11.0%
3) No prior treatment using DDP-4 inhibitor
4) No change of oral hypoglycemic drugs for 3 months prior
2. Patients over 20 years-old.
3. Patients who have been informed and have understood the full explanation of this study, and have agreed and given prior written consent.

Key exclusion criteria

1. Type 1 diabetes, diabetic ketoacidosis or diabetic coma
2. Severe liver or kidney dysfunction
3. Severe infection or traumatic injury
4. In a perioperative period of major surgery
5. Anti-glutamic acid decarboxylase (GAD) antibody>=10U/ml
6. Poorly controlled hypertension; systolic blood pressure>=160mmHg or diastolic blood pressure>=100mmHg
7. Pregnant female, female with possibility of pregnancy and breast-feeding female
8. History of hypersensitivity to targeted medication
9. History of severe cardiovascular or cerebrovascular disease in 6 months
10. Any other factors that may disqualify the patient

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takashi Kitaoka

Organization

Nagasaki University Graduate School of Biomedical Sciences

Division name

Department of Ophthalmology & Visual Sciences

Zip code


Address

1-7-1 Sakamoto, Nagasaki city, Japan

TEL

095-819-7345

Email

tkitaoka@nagasaki-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yuki Maekawa

Organization

Nagasaki University Graduate School of Biomedical Sciences

Division name

Department of Ophthalmology & Visual Sciences

Zip code


Address

1-7-1 Sakamoto, Nagasaki city, Japan

TEL

095-819-7345

Homepage URL


Email

maekaway@nagasaki-u.ac.jp


Sponsor or person

Institute

Nagasaki University Graduate School of Biomedical Sciences

Institute

Department

Personal name



Funding Source

Organization

Nagasaki University Graduate School of Biomedical Sciences

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

1. Department of Metabolism/Diabetes and Clinical Nutrition, Nagasaki University Hospital
2. Department of Ophthalmology, Nagasaki University Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

長崎大学病院(長崎県)/Nagasaki University Hospital


Other administrative information

Date of disclosure of the study information

2012 Year 12 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2012 Year 12 Month 31 Day

Date of IRB


Anticipated trial start date

2013 Year 01 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 12 Month 26 Day

Last modified on

2013 Year 12 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011309


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name